- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06041386
REIMAGINE - Utvärdering av mepolizumab i verkligheten vid svår astma som uppnår behandling med klinisk remission, en prospektiv studie (REIMAGINE)
En prospektiv, verklig, interventionsstudie för att utvärdera effekten av mepolizumab på att uppnå klinisk remission hos deltagare med svår astma
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Kortrijk, Belgien, 8500
- GSK Investigational Site
-
Liège, Belgien, 4000
- GSK Investigational Site
-
-
-
-
-
Brest, Frankrike, 29200
- GSK Investigational Site
-
Cannes, Frankrike, 06614
- GSK Investigational Site
-
Lille, Frankrike, 59000
- GSK Investigational Site
-
Lyon, Frankrike, 69004
- GSK Investigational Site
-
Strasbourg, Frankrike, 67091
- GSK Investigational Site
-
Toulouse, Frankrike, 31059
- GSK Investigational Site
-
-
-
-
California
-
La Jolla, California, Förenta staterna, 92037
- GSK Investigational Site
-
Newport Beach, California, Förenta staterna, 92663
- GSK Investigational Site
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 71105
- GSK Investigational Site
-
Colorado Springs, Colorado, Förenta staterna, 80923
- GSK Investigational Site
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06510
- GSK Investigational Site
-
-
Florida
-
Homestead, Florida, Förenta staterna, 33032-8185
- GSK Investigational Site
-
Jacksonville, Florida, Förenta staterna, 32209
- GSK Investigational Site
-
Miami, Florida, Förenta staterna, 33125
- GSK Investigational Site
-
Plantation, Florida, Förenta staterna, 33317
- GSK Investigational Site
-
-
Georgia
-
Adairsville, Georgia, Förenta staterna, 30103
- GSK Investigational Site
-
Columbus, Georgia, Förenta staterna, 31904
- GSK Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40509-1801
- GSK Investigational Site
-
Owensboro, Kentucky, Förenta staterna, 42301
- GSK Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 34452
- GSK Investigational Site
-
-
Maryland
-
Glenn Dale, Maryland, Förenta staterna, 20769
- GSK Investigational Site
-
Towson, Maryland, Förenta staterna, 21204
- GSK Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48103
- GSK Investigational Site
-
-
Minnesota
-
Linwood, Minnesota, Förenta staterna, 55092
- GSK Investigational Site
-
Rochester, Minnesota, Förenta staterna, 55905-0001
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Förenta staterna, 89052-5015
- GSK Investigational Site
-
-
New York
-
Rochester, New York, Förenta staterna, 14607
- GSK Investigational Site
-
Schenectady, New York, Förenta staterna, 12308
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19140
- GSK Investigational Site
-
Philadelphia, Pennsylvania, Förenta staterna, 19141
- GSK Investigational Site
-
-
South Carolina
-
Union, South Carolina, Förenta staterna, 29379-7409
- GSK Investigational Site
-
-
Texas
-
Cypress, Texas, Förenta staterna, 77429-1439
- GSK Investigational Site
-
Kerrville, Texas, Förenta staterna, 78028
- GSK Investigational Site
-
McKinney, Texas, Förenta staterna, 75069
- GSK Investigational Site
-
-
-
-
-
Genova, Italien, 16132
- GSK Investigational Site
-
Monserrato CA, Italien, 09042
- GSK Investigational Site
-
Naples, Italien, 80131
- GSK Investigational Site
-
Pieve Di Soligo TV, Italien, 131044
- GSK Investigational Site
-
Roma, Italien, 00128
- GSK Investigational Site
-
Roma, Italien, 161
- GSK Investigational Site
-
Rozzano, Italien, 20089
- GSK Investigational Site
-
Verona, Italien, 37126
- GSK Investigational Site
-
-
-
-
-
Gifu, Japan, 509-6134
- GSK Investigational Site
-
Kagawa, Japan, 760-0018
- GSK Investigational Site
-
Tokyo, Japan, 142-8666
- GSK Investigational Site
-
Tokyo, Japan, 173-8606
- GSK Investigational Site
-
Tokyo, Japan, 105-0003
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B0M3
- GSK Investigational Site
-
Calgary, Alberta, Kanada
- GSK Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3L 1Z5
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1E2
- GSK Investigational Site
-
-
-
-
-
?Od?, Polen, 90-153
- GSK Investigational Site
-
Gdansk, Polen, 80-214
- GSK Investigational Site
-
Lodz, Polen, 92-213
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08025
- GSK Investigational Site
-
Girona, Spanien, 17005
- GSK Investigational Site
-
Valencia, Spanien, 46015
- GSK Investigational Site
-
-
-
-
-
Bonn, Tyskland, 53119
- GSK Investigational Site
-
Hohenstein-Ernsttal, Tyskland, 9337
- GSK Investigational Site
-
Schleswig, Tyskland, 53123
- GSK Investigational Site
-
-
Hesse
-
Darmstadt, Hesse, Tyskland, 64283
- GSK Investigational Site
-
Frankfurt am Main, Hesse, Tyskland, 60389
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Tyskland, 52074
- GSK Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
- No NUCALA use in the 6 months prior to enrollment.
- Participants with greater than or equal to (≥)60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician.
- Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
- Written informed consent
Exclusion Criteria:
- Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
- Participants currently on maintenance OCS or intramuscular corticosteroids.
- Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment
- Participants participating in an interventional study with a treatment intervention
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Group 1
Participants with a clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care. |
Mepolizumab will be prescribed based on physician decision. Lung function via spirometry will be collected. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage (%) of Participants Achieving 4-Component Clinical Remission
Tidsram: At month 12
|
4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function. |
At month 12
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Annualized Rates of Clinically Significant Asthma Exacerbations (CSE) and CSE Leading to Hospitalization/ Emergency Room (ER) Visits
Tidsram: At month 12
|
CSE is defined as a deterioration in asthma requiring (1) the initiation of systemic corticosteroids and/or (2) an ER visit and/or hospital admission. |
At month 12
|
|
Percentage of Participants Achieving OCS Sparing Remission
Tidsram: At month 12
|
OCS sparing is defined as (a) No clinically significant asthma exacerbations during the period of interest (b) No OCS use for asthma at the time point of interest. |
At month 12
|
|
Percentage of Participants Achieving 3-Component Clinical Remission
Tidsram: At month 12
|
3-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an ACT |
At month 12
|
|
Mean Change from Baseline in Mini-Asthma Quality of Life Questionnaire (AQLQ) Overall Score
Tidsram: Baseline and at month 12
|
The mini-AQLQ overall score is a reduced version of the AQLQ which includes 15 items. The minimally clinically important difference (MCID) is 0.5. The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability |
Baseline and at month 12
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: GSK Clinical Trials, GlaxoSmithKline
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 219871
- 2023 (U.S.S. NIH-anslag/kontrakt)
- 2023-509026-21-00 (Registeridentifierare: CTIS (EU))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Tidsram för IPD-delning
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Kriterier för IPD Sharing Access
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .